Reported Earlier, Tenax Reports New Phase 3 Data Supporting TNX-103 In Pulmonary Hypertension Patients
Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax" or "Tenax Therapeutics" or the "Company") today announced that additional results from the Phase 3 LEVEL clinical trial evaluating TNX-103 (oral
Tenax shared new test results from a late-stage medicine trial that showed promise for treating a heart-lung condition. When a medicine moves forward in testing, it's a signal the company is making progress—though the medicine still needs final approval before patients can use it.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.